key: cord-0931317-jkkvfk6n
authors: Minhas, Anum; Shade, Julie K.; Cho, Sung-Min; Michos, Erin D.; Metkus, Thomas; Gilotra, Nisha A.; Sharma, Garima; Trayanova, Natalia; Hays, Allison G.
title: The role of sex and inflammation in cardiovascular outcomes and mortality in COVID-19
date: 2021-05-08
journal: Int J Cardiol
DOI: 10.1016/j.ijcard.2021.05.011
sha: 7a7d887c925d1a64e6fe46b4ee9b0d529c947ffc
doc_id: 931317
cord_uid: jkkvfk6n

OBJECTIVE: Higher mortality in COVID-19 in men compared to women is recognized, but sex differences in cardiovascular events are less well established. We aimed to determine the independent contribution of sex to stroke, myocardial infarction and death in the setting of COVID-19 infection. METHODS: We performed a retrospective cohort study of hospitalized COVID-19 patients in a racially/ethnically diverse population. Clinical features, laboratory markers and clinical events were initially abstracted from medical records, with subsequent clinician adjudication. RESULTS: Of 2060 patients, myocardial injury (32% vs 23%, p = 0.019), acute myocardial infarction (2.7% vs 1.6%, p = 0.114), and ischemic stroke (1.8% vs 0.7%, p = 0.007) were more common in men vs women. In-hospital death occurred in 160 men (15%) vs 117 women (12%, p = 0.091). Men had higher odds of myocardial injury (odds ratio (OR) 2.04 [95%CI 1.43–2.91], p < 0.001), myocardial infarction (1.72 [95%CI 0.93–3.20], p = 0.085) and ischemic stroke (2.76 [95%CI 1.29–5.92], p = 0.009). Despite adjustment for demographics and cardiovascular risk factors, male sex predicted mortality (HR 1.33; 95% CI:1.01–1.74; p = 0.041). While men had significantly higher markers of inflammation, in sex-stratified analyses, increase in interleukin-6, C-reactive protein, ferritin and d-dimer were predictive of mortality and myocardial injury similarly in both sexes. CONCLUSIONS: Adjusted odds of myocardial injury, ischemic stroke and all-cause mortality, but not myocardial infarction, are significantly higher in men. Higher inflammatory markers are present in men but associated similarly with risk in both men and women. These data suggest that adverse cardiovascular outcomes in men vs. women are independent of cardiovascular comorbidities.

Of 2060 patients, myocardial injury (32% vs 23%, p=0.019), acute myocardial infarction (2.7% vs 1.6%, p=0.114), and ischemic stroke (1.8% vs 0.7%, p=0.007) were more common in men vs women. In-hospital death occurred in 160 men (15%) vs 117 women (12%, p=0.091). Men had higher odds of myocardial injury ( 95% CI:1.01-1.74; p=0.041). While men had significantly higher markers of inflammation, in sex-stratified analyses, increase in interleukin-6, C-reactive protein, ferritin and d-dimer were predictive of mortality and myocardial injury similarly in both sexes.

Adjusted odds of myocardial injury, ischemic stroke and all-cause mortality, but not myocardial infarction, are significantly higher in men. Higher inflammatory markers are present in men but associated similarly with risk in both men and women. These data suggest that adverse cardiovascular outcomes in men vs. women are independent of cardiovascular comorbidities.

COVID-19, caused by coronavirus SARS-CoV2, carries high mortality and morbidity, especially for cardiovascular disease (CVD) [1, 2] . Men have consistently higher unadjusted and adjusted mortality from COVID-19 compared to women as reported by various international agencies and prior literature [3] [4] [5] [6] . This sex difference in mortality may be related to greater underlying comorbidities in men compared to women, such as hypertension and CVD, which have been linked to increased severity of COVID-19 [5, 7, 8] . In addition, two factors that may contribute to mortality in COVID-19 include myocardial injury defined by troponin elevation, and increased systemic inflammation, both independently associated with in-hospital mortality [1, 9, 10] . However, little is known regarding sex differences in myocardial injury, systemic inflammation and CVD outcomes, although plausible explanations for sex differences include variations in immune response and angiotensin converting enzyme (ACE) 2 expression. We hypothesized that adverse cardiovascular (CV) outcomes occur more frequently in men J o u r n a l P r e -p r o o f compared to women in the setting of COVID-19, even after adjusting for demographics and CV comorbidities. Further, as recent evidence suggests a link between increased inflammation and worse outcomes, [11] we aimed to perform a sex-stratified evaluation of inflammatory markers and their association with mortality and CV outcomes in hospitalized patients with COVID-19.

Data were obtained from the Johns Hopkins Health System COVID-19 Precision Medicine Analytic Platform Registry (JH-CROWN) on a racially and ethnically diverse patient population. This registry extrapolates data from 5 hospitals using electronic medical records. Consecutive adult patients (>18 years of age) with confirmed COVID-19 by reverse transcriptase polymerase chain reaction test, who were admitted and died, or were discharged between March 1, 2020 and July 4, 2020, were included. Only the index hospitalization for each patient was included. Any patients who were still admitted after the end date were excluded.

Comorbidities and clinical events were obtained using ICD-10 codes or key words (Supplement), and sex and race were self-identified. Myocardial infarction and ischemic and hemorrhagic stroke, were further adjudicated by a neurologist, 2 cardiologists and a research nurse [10, 12] . All laboratory data were obtained using the first recorded values during hospitalization. COVID-19 patient management at our institution is based on specific institutional protocols, which include protocols for medical interventions, J o u r n a l P r e -p r o o f Journal Pre-proof laboratory measurements and cardiac and venous thromboembolism evaluation and management. The study was approved by the Johns Hopkins University Institutional Review Board. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

We compared demographics, comorbidities, laboratory values and clinical events using parametric two-sample Student's t-test for normally distributed continuous variables, nonparametric Mann-Whitney U test for non-normally distributed continuous variables, or Chi-squared test for categorical variables. Unadjusted and adjusted Cox proportionalhazard models were used to estimate hazard ratios (HR) of death. Model 1 included adjustment for age, race and body mass index (BMI) and Model 2 added CV comorbidities (hypertension, diabetes, heart failure, coronary artery disease and history of smoking). Logistic regression was performed for myocardial injury (defined as troponin I >0.04 ng/mL) with models 1 and 2. For myocardial infarction and ischemic stroke, only model 1 for logistic regression was conducted given a smaller number of events. Inflammatory and cardiovascular biomarkers were divided into quintiles. Given that biomarkers were not available for the entire cohort, analyses were used to identify differences in demographics and comorbidities among patients with/without laboratory values available. Identifiable differences were considered potential confounders and included for adjustment in Cox and logistic regression looking at sex-stratified association of biomarker elevation with all-cause mortality and myocardial injury. For ischemic stroke and myocardial infarction, inflammatory markers were only evaluated J o u r n a l P r e -p r o o f Journal Pre-proof without adjustment given fewer events. All proportional hazard assumptions were confirmed.

Of 2060 patients, 1088 were men. Medial length of stay for men was 7.0 (3. (Figure 1 ). Interleukin-6 was associated with increased odds of ischemic stroke (Figure 1 ).

We present sex data comparing important cardiovascular indices among men and women from a large cohort of racially/ethnically diverse hospitalized patients with COVID-19. Although men had more underlying CV comorbidities, after adjusting for these, men had a significantly increased risk of death compared to women. Moreover, the risk of both myocardial injury and ischemic stroke was higher in men, even after adjustment for clinical confounders. Finally, we report markedly increased levels of systemic inflammatory markers in men compared to women early during hospital admission for COVID-19, although there was no notable difference in the ability of inflammatory markers to predict adverse outcomes between sexes. To our knowledge, this is one of the first studies to investigate sex differences in COVID-19 in important CV outcomes and the degree of systemic inflammation after adjustment for comorbidities [6, 13] . These findings support differences in sex-specific responses, but suggest that these differences are likely independent of common cardiovascular comorbidities, as has previously been advocated but not well studied [8, 14, 15] .

Prior studies have shown that elevated systemic inflammation, as measured by clinical inflammatory biomarkers, is associated with COVID-19 severity [11] . However, there are few data on sex-stratified analyses of systemic inflammation and the extent of association with mortality and cardiovascular outcomes. In addition, although women J o u r n a l P r e -p r o o f Journal Pre-proof have been reported to have higher levels of inflammatory markers in the outpatient setting, such as interleukin-6, compared to men, [16] our study in acutely ill patients with COVID-19 showed that men had significantly higher levels of several inflammatory markers including interleukin-6, C-reactive protein and ferritin. Despite high levels of acute inflammation in men, we demonstrate similar increases in the risk of mortality and odds of myocardial injury, myocardial infarction and ischemic stroke with elevations in inflammatory biomarkers between men and women. These findings raise suspicion that perhaps men are more likely to have a hyper-inflammatory response than women, although this alone may not explain the observed sex differences in mortality and cardiovascular outcomes. Recent studies also suggest that hyperactivation of the coagulation system, perhaps as demonstrated by rise in D-dimer, may be associated with myocardial injury and COVID-19 mortality [17] [18] [19] . COVID-19-related coagulopathy may result in the occurrence of thrombotic microangiopathy in various organs [20] . While we did not specifically investigate coagulopathy in our study and did not find D-dimer to be differentially elevated among men and women, it is certainly possible that COVID-19 related coagulopathy may be contributing to outcomes such as myocardial infarction, ischemic stroke or death.

Limitations of this work include retrospective study design. Additionally, all laboratory data were measured as clinically indicated, which raises potential selection bias. However, we adjusted for possible confounders to limit selection bias.

In conclusion, men are at significantly greater risk than women for myocardial injury, ischemic stroke and all-cause mortality in the setting of hospitalization with COVID-19.

This increased risk in men remains despite adjustment for demographics and cardiovascular comorbidities. In addition, increased inflammatory markers are associated with a greater likelihood of developing myocardial injury, ischemic stroke and mortality, although this association is similar between men and women. These data support male sex as an independent risk factor of myocardial injury, ischemic stroke and mortality in COVID-19 and increased monitoring for men for cardiovascular events, perhaps through use of inflammatory markers, should be considered.

J o u r n a l P r e -p r o o f Legend: *Hazard ratios of death and odds ratios of myocardial injury are adjusted for age, race, body mass index, and history of hypertension, diabetes, coronary artery disease, congestive heart failure and smoking J o u r n a l P r e -p r o o f

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Impact of sex and gender on COVID-19 outcomes in Europe

COVID-19 Sex-disaggregated Data Tracker

Sex Differences in Coronavirus Disease 2019 (COVID-19) Hospitalization and Mortality

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study

Sex-differences in mortality rates and underlying conditions for COVID-19 deaths in England and Wales

A comparison of mortalityrelated risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis

Association of inflammatory markers with the severity of COVID-19: A meta-analysis

An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

Sex Differences in Mortality From COVID-19 Pandemic

Biological sex impacts COVID-19 outcomes

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

Sex differences in monocyte expression of IL-6: role of autonomic mechanisms

The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans, The Lancet Respiratory Medicine

Author Agreement Form -International Journal of Cardiology Manuscript Title: The role of sex and inflammation in cardiovascular outcomes and mortality in COVID-19

Anum Minhas, MD 1,2

This statement is to certify that all authors have seen and approved the manuscript being submitted, have contributed significantly to the work, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to the

has not received prior publication and is not under consideration for publication elsewhere. We adhere to the statement of ethical publishing as appears in the International of Cardiology (citable as

On behalf of all Co-Authors, the corresponding Author shall bear full responsibility for the submission. Any changes to the list of authors, including changes in order, additions or removals will require the submission of a new author agreement form approved and signed by all the original and added submitting authors

The data utilized for this publication were part of the JH-CROWN: The COVID PMAP Registry which is based on the contribution of many patients and clinicians.